Nectar Lifescience Ltd

₹ 11.8 -0.67%

16 Jun 2:55 p.m.

About

Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations^[1]

Key Points

Business Overview:^[1]
NLL is a research-driven manufacturer
of Active Pharmaceutical Ingredients, intermediates, and finished dosage
forms, specializing in anti-infectives
like Cephalosporins. It also serves
as a CMO for global pharma
innovators.

Website BSE NSE - BE

Market Cap ₹ 229 Cr.
Current Price ₹ 11.8
High / Low ₹ 23.9 / 9.20
Stock P/E
Book Value ₹ 30.0
Dividend Yield 0.00 %
ROCE -4.88 %
ROE -7.46 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Stock is trading at 0.40 times its book value
Promoter holding has increased by 6.93% over last quarter.

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -73.5% over past five years.
Company has a low return on equity of -5.83% over last 3 years.
Contingent liabilities of Rs.134 Cr.
Working capital days have increased from 8,908 days to 26,618 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	389	394	398	452	441	359	6	0	0	5	1	0	1
	371	359	371	410	393	319	6	0	0	6	0	2	59
Operating Profit	18	36	27	42	48	40	-1	-0	-0	-1	1	-2	-57
OPM %	5%	9%	7%	9%	11%	11%	-10%	-500%	-500%	-16%	77%		-4,437%
	18	0	11	0	1	1	7	8	-130	-62	-176	35	-24
Interest	20	18	21	25	24	20	0	0	0	0	0	30	6
Depreciation	15	15	15	15	15	15	0	0	0	1	0	0	0
Profit before tax	2	3	2	2	11	5	5	8	-130	-64	-176	3	-88
Tax %	-145%	41%	38%	36%	95%	40%	-2%	2%	-0%	-1%	0%	-339%	-22%
	4	2	1	2	1	3	6	8	-130	-63	-176	14	-68
EPS in Rs	0.16	0.08	0.05	0.07	0.03	0.13	0.25	0.35	-5.80	-2.82	-7.85	0.64	-3.50
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,638	1,674	1,635	1,874	2,779	2,363	1,541	1,665	1,520	1,682	1,664	2
	1,371	1,436	1,411	1,638	2,514	2,143	1,432	1,507	1,467	1,530	1,694	61
Operating Profit	267	239	224	236	264	220	109	159	53	152	-30	-59
OPM %	16%	14%	14%	13%	10%	9%	7%	10%	3%	9%	-2%	-2,920%
	20	6	23	6	6	4	-22	11	43	15	5	-228
Interest	126	123	117	115	148	126	112	79	79	87	75	36
Depreciation	77	57	62	64	63	61	60	57	59	61	62	0
Profit before tax	85	64	67	63	59	37	-85	34	-42	18	-162	-323
Tax %	22%	15%	18%	17%	19%	15%	-14%	26%	-43%	73%	-30%	-9%
	66	54	55	52	48	32	-73	25	-24	5	-114	-293
EPS in Rs	2.95	2.42	2.47	2.33	2.12	1.42	-3.27	1.12	-1.08	0.22	-5.07	-15.08
Dividend Payout %	3%	4%	2%	2%	2%	4%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-49%
5 Years:	-74%
3 Years:	-89%
TTM:	-100%

Compounded Profit Growth
10 Years:	%
5 Years:	-4%
3 Years:	4%
TTM:	50%

Stock Price CAGR
10 Years:	-10%
5 Years:	-22%
3 Years:	-16%
1 Year:	-49%

Return on Equity
10 Years:	-1%
5 Years:	-4%
3 Years:	-6%
Last Year:	-7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	22	22	22	22	22	22	22	22	22	22	22	19
Reserves	936	932	984	1,036	1,083	1,114	1,040	1,065	1,042	1,047	934	563
	925	962	878	955	903	779	903	860	754	636	582	0
	628	640	696	710	696	718	423	443	371	486	509	39
Total Liabilities	2,510	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	622
	934	906	881	852	825	785	772	723	662	643	633	105
CWIP	91	99	102	100	100	115	99	85	78	66	57	0
Investments	1	1	1	1	1	0	1	1	1	1	1	13
	1,485	1,551	1,597	1,771	1,780	1,733	1,517	1,582	1,449	1,482	1,357	504
Total Assets	2,510	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	622

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	144	169	199	65	239	285	21	95	134	225	169	-349
	-60	-77	-18	-29	-26	-33	-29	17	52	-17	-42	1,208
	-61	-89	-204	-40	-201	-252	11	-119	-186	-205	-128	-767
Net Cash Flow	23	3	-23	-4	12	-0	4	-8	-0	2	-1	93
Free Cash Flow	64	87	174	32	204	249	-10	110	183	195	126	-341
CFO/OP	56%	74%	92%	33%	96%	134%	23%	60%	252%	148%	-574%	594%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	99	107	112	119	73	61	89	98	67	82	76	0
Inventory Days	253	260	270	226	151	192	185	197	212	215	184
Days Payable	146	154	167	142	80	104	108	112	100	127	117
Cash Conversion Cycle	207	213	215	203	145	150	166	182	179	170	143	0
Working Capital Days	40	41	45	67	46	53	6	73	77	63	43	26,618
ROCE %	11%	10%	10%	9%	10%	8%	3%	5%	-0%	6%	-5%	-5%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Drug Master Files (DMF) Filed
Number ・Standalone data

xxx	x,xxx	xx	xx	xx	xx	xx	xxx	xxx		x
xxx	xx		xx	xx	xx	xx	xx	xx	xx	xx
xx.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
xxx	xxx	xx	xx	xx	xx	xx
	x,xxx	x,xxx	x,xxx		x,xxx	x,xxx			x,xxx	x,xxx
xxx	x,xxx					x,xxx	x,xxx		x,xxx
xxx	xx						xxx		xxx
x,xxx	x,xxx						xxx		xxx

Please log in to see hidden values.

Global Export Reach (Countries)
Count ・Standalone data

Empty Hard Gelatin Capsule (EHGC) Capacity
Billion Shells ・Standalone data

ANDA Filings (US)
Number ・Standalone data

Headcount (Permanent Employees)
Employees ・Standalone data

API Production Capacity
MT ・Standalone data

Formulations Capacity - Injectable Vials
Million per year ・Standalone data

Formulations Capacity - Tablets
Million per year ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	44.53%	44.53%	44.53%	44.91%	44.91%	51.84%
	16.00%	16.02%	16.12%	16.98%	16.60%	3.24%	0.73%	1.65%	0.82%	0.62%	0.52%	0.60%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.19%	0.08%	0.00%	0.01%
	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	5.84%	4.03%
	28.18%	28.17%	28.05%	27.20%	27.57%	40.94%	54.72%	53.64%	54.45%	54.37%	48.73%	43.52%
No. of Shareholders	61,582	60,283	60,761	59,946	58,230	66,741	69,482	69,241	71,977	76,470	78,124	74,834

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	44.53%	51.84%
	3.39%	3.38%	2.90%	2.90%	2.62%	1.67%	16.07%	16.98%	1.65%	0.60%
	0.83%	0.36%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.01%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.02%	0.02%	0.02%	4.03%
	39.98%	40.46%	41.20%	41.30%	41.58%	42.53%	28.12%	27.20%	53.64%	43.52%
No. of Shareholders	36,791	38,709	41,876	40,012	47,394	64,012	62,874	59,946	69,241	74,834

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Nectar Lifescience Ltd

Nectar Lifescience Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls